Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Sanofi ADR (SNY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sanofi ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
49.36 +2.75    +5.90%
16:00:04 - Closed. Currency in USD ( Disclaimer )
After Hours
49.00
-0.36
-0.73%
19:58:43 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 6,464,961
  • Bid/Ask: 47.05 / 49.36
  • Day's Range: 48.65 - 49.83
Sanofi ADR 49.36 +2.75 +5.90%

NASDAQ:SNY Financials

 
A brief overview of the NASDAQ:SNY financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Sanofi ADR over time.

Sanofi reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was EUR 10,919 million compared to EUR 10,725 million a year ago. Net loss was EUR 555 million compared to net income of EUR 3,111 million a year ago. Basic loss per share from continuing operations was EUR 0.44 compared to basic earnings per share from continuing operations of EUR 2.48 a year ago.For the full year, sales was EUR 43,070 million compared to EUR 42,997 million a year ago. Net income was EUR 5,400 million compared to EUR 8,371 million a year ago. Basic earnings per share from continuing operations was EUR 4.31 compared to EUR 6.69 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SNY Income Statement

Gross margin TTM 69.12%
Operating margin TTM 19.99%
Net Profit margin TTM 11.73%
Return on Investment TTM 8.17%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 11790 12698 10588 10863
Gross Profit 7762 8857 7325 7784
Operating Income 815 3477 1546 2821
Net Income -555 2525 1435 1995

SNY Balance Sheet

Quick Ratio MRQ 0.71
Current Ratio MRQ 1.27
LT Debt to Equity MRQ 19.38%
Total Debt to Equity MRQ 24.88%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 126464 125353
Total Liabilities 52111 52406
Total Equity 74353 72947 72947 75152

SNY Cash Flow Statement

Cash Flow/Share TTM 8.18
Revenue/Share TTM 36.71
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of EUR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SNY Comments

Write your thoughts about Sanofi ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Moshe Ohr
Moshe Ohr Aug 10, 2022 11:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any idea what is behind the price change today?Thank you!
Moshe Ohr
Moshe Ohr Jul 28, 2022 3:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good News 🗞️
gino freeboter
gino freeboter May 03, 2021 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what is going on?why drop 4% inpremarket?
Aspar Badur
Aspar Badur May 03, 2021 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
don’t know 🤷‍♂️
Päivi Saarela
Päivi Saarela Apr 26, 2021 8:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NEWS: Sanofi agrees to make Moderna COVID-19 vaccine in the U.S. starting in September
Brad Eff
Brad Eff Mar 31, 2021 10:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Announcement RIGHT NOW about a +$900 Million investment in Canada
Akposiegbe Kelvin
Akposiegbe Kelvin Feb 14, 2021 10:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
sanofi said it's vaccine will be available next year..
Renata Hoffmann
Renata Hoffmann Feb 14, 2021 10:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
but they have more products in pipeline...not just the vaccine
Renata Hoffmann
Renata Hoffmann Feb 11, 2021 8:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Whi is it falling? FDA approval end its going down?
Omprakash Maurya
Omprakash Maurya Feb 05, 2021 10:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Next target 52 buy at 48
Tejasvi Gogna
Tejasvi Gogna Aug 13, 2020 7:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ARPO a small stock has given me 22% rise , that too on a day when all others have disappointed . Nova , Mrna , Bntx , Astra , Sanofi ... Seriously I salute to the guys running ARPO. .. its been so stable when all others are horribly unpredictable. ARPO has hd its base value and maintained its 1.5 level and Now its on 1.83 and after market is up again. highly recommended if someone wants to invest 1000 dollars and forget it for a while , I am sure its worth putting your 💰......
RoB Wanger
RoB Wanger Jul 31, 2020 11:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://ca.finance.yahoo.com/news/u-pay-2-1-billion-122206294.html
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email